All News

Patients who received cabozantinib experienced a PFS of 8.5 months vs 5.6 months with placebo, a subgroup analysis from the CABINET trial found.

Additionally, data show a trend towards improved overall survival with TACE plus camrelizumab/rivoceranib in the phase 2 CARES-005 study.

Sintilimab plus neoadjuvant chemoradiotherapy yielded a pCR rate of 60% vs 13% from sintilimab plus chemotherapy in patients with locally advanced ESCC.

2mg, 3mg, and 5mg extended-release capsules of everolimus have been approved for patients with TSC-associated SEGA by the FDA.

The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Phase 1/2 SYLT-023 trial evaluated the efficacy and safety of tislelizumab plus chemotherapy in patients with advanced, HER2-negative, mismatch repair–proficient gastric/GEJ cancer.

Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.

Adding trastuzumab and pertuzumab to chemotherapy conferred higher toxicity among patients with HER2-positive gastric cancers in the INNOVATION trial.

Results from the CheckMate 649 trial showed continued efficacy at 5 years in the nivolumab combination for patients with gastric/GEJ/esophageal cancer.

The CheckMate 649 trial found that nivolumab plus chemotherapy lead to a median OS of 14.3 months vs 10.3 months for chemotherapy alone in several gastrointestinal cancers.

Select patients may be eligible to continue treatment with tabelecleucel or ATA3219 in accordance with study protocols.

Phase 2 results show clinical responses and survival benefits in patients with confirmed HER2-positive expression in gastric/gastroesophageal cancer.

SHR-1701 plus CAPOX chemotherapy elicited fewer chemo delays and dose reductions and improved AE data vs placebo plus CAPOX in HER2-negative gastric/GEJ cancer.

Results from the phase 2 FDZL-001 trial showed high OS and PFS rates when camrelizumab plus Nab-POF was used to treat patients with gastric/GEJ cancer.

A phase 1a/1b trial showed that ZL-1310 elicited an ORR of 74%, all of which were PRs, in patients with SCLC who received prior chemotherapy.

Interim phase 3 results revealed a median survival of at least 13.5 months with galinpepimut-S vs 6 months with standard of care in acute myeloid leukemia.

Data show a trend towards a reduced risk of death with fulvestrant vs anastrozole among patients with nonvisceral disease in the phase 3 FALCON trial.

Trastuzumab/pertuzumab elicited similar efficacy and fewer high-grade AEs vs cetuximab/irinotecan in RAS/BRAF wild-type, HER2–positive metastatic CRC.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Of note, lung cancer incidence was higher among women younger than 65 compared with their male counterparts in 2021.

Patients who received the isatuximab combination in the IMROZ trial experienced prolonged MRD-negativity, which correlated with improved PFS.

In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.

Doxycycline/minocycline, clindamycin, chlorhexidine, and a ceramides-based noncomedogenic moisturizer reduced skin- and nail-related AEs in NSCLC.

Additionally, adding nab-paclitaxel to gemcitabine/cisplatin confers more toxicity than gemcitabine/cisplatin alone in the phase 3 SWOG S1815 trial.

Everolimus plus lanreotide elicited a PFS of 29.7 months compared with 11.5 months from everolimus monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.

Acalabrutinib improves efficacy in high-risk patients like those with TP53 mutations, those with complex cytogenetics, and those with high proliferative rates in MCL.

Sessions of interest at the 2025 Gastrointestinal Cancers Symposium will include data on colorectal cancer, pancreatic ductal adenocarcinoma, and more.

RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.

Results from a Chinese phase 1 trial reveal that anlotinib plus EGFR-TKIs demonstrated manageable toxicity in NSCLC pre-treated with EGFR-TKIs.